Literature DB >> 9653050

Structure-function studies of the HIV-1 coreceptors.

J F Berson1, R W Doms.   

Abstract

Ten seven-transmembrane-domain G protein-coupled receptors have been identified that are functional HIV-1, HIV-2 and SIV coreceptors. However, the specific structures these receptors have in common that enable them to mediate HIV entry are unknown. Structure-function analyses have revealed that the determinants of coreceptor activity are distinct for each coreceptor, coreceptor activity is dependent on multiple extracellular domains, and various envelope proteins may interact differently with the same coreceptor. G protein coupling and receptor internalization are not required for fusion and infection of established cell lines, or for inhibition of infection by chemokines. The structure-function studies have also helped determine the mechanism by which previously described small molecules inhibit HIV-1 entry. Finally, these studies have led to a hypothesis as to how coreceptor utilization evolves during the course of an infection. Copyright 1998 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9653050     DOI: 10.1006/smim.1998.0130

Source DB:  PubMed          Journal:  Semin Immunol        ISSN: 1044-5323            Impact factor:   11.130


  13 in total

Review 1.  Chemokine receptors and neural function.

Authors:  Charlene Cho; Richard J Miller
Journal:  J Neurovirol       Date:  2002-12       Impact factor: 2.643

2.  Cooperation of the V1/V2 and V3 domains of human immunodeficiency virus type 1 gp120 for interaction with the CXCR4 receptor.

Authors:  B Labrosse; C Treboute; A Brelot; M Alizon
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

3.  Targeted entry via somatostatin receptors using a novel modified retrovirus glycoprotein that delivers genes at levels comparable to those of wild-type viral glycoproteins.

Authors:  Fang Li; Byoung Y Ryu; Robin L Krueger; Scott A Heldt; Lorraine M Albritton
Journal:  J Virol       Date:  2011-10-19       Impact factor: 5.103

4.  Use of a gp120 binding assay to dissect the requirements and kinetics of human immunodeficiency virus fusion events.

Authors:  B J Doranz; S S Baik; R W Doms
Journal:  J Virol       Date:  1999-12       Impact factor: 5.103

5.  A human immunodeficiency virus type 1 isolate from an infected person homozygous for CCR5Delta32 exhibits dual tropism by infecting macrophages and MT2 cells via CXCR4.

Authors:  Hassan M Naif; Anthony L Cunningham; Mohammed Alali; Shan Li; Najla Nasr; Marc M Buhler; Dominique Schols; Erik de Clercq; Graeme Stewart
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

6.  An extended CCR5 ECL2 peptide forms a helix that binds HIV-1 gp120 through non-specific hydrophobic interactions.

Authors:  Meital Abayev; Adi Moseri; Oren Tchaicheeyan; Naama Kessler; Boris Arshava; Fred Naider; Tali Scherf; Jacob Anglister
Journal:  FEBS J       Date:  2015-03-18       Impact factor: 5.542

7.  Cell-to-cell contact facilitates HIV transmission from lymphocytes to astrocytes via CXCR4.

Authors:  Guan-Han Li; Caroline Anderson; Laura Jaeger; Thao Do; Eugene O Major; Avindra Nath
Journal:  AIDS       Date:  2015-04-24       Impact factor: 4.177

8.  N-linked glycosylation of CXCR4 masks coreceptor function for CCR5-dependent human immunodeficiency virus type 1 isolates.

Authors:  D J Chabot; H Chen; D S Dimitrov; C C Broder
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

9.  Glycosphingolipids promote entry of a broad range of human immunodeficiency virus type 1 isolates into cell lines expressing CD4, CXCR4, and/or CCR5.

Authors:  P Hug; H M Lin; T Korte; X Xiao; D S Dimitrov; J M Wang; A Puri; R Blumenthal
Journal:  J Virol       Date:  2000-07       Impact factor: 5.103

10.  CD4-independent use of Rhesus CCR5 by human immunodeficiency virus Type 2 implicates an electrostatic interaction between the CCR5 N terminus and the gp120 C4 domain.

Authors:  G Lin; B Lee; B S Haggarty; R W Doms; J A Hoxie
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.